办公地点

204室

办公电话

0431-85619716

邮箱

jguo@jlu.edu.cn

教育背景

2001-2005 BSc, Bioscience, School of Life Sciences, Northeast Normal University

2001-2005 东北师范大学，生命科学学院，生物科学，学士

2005-2007 MSc, Biotechnology, Department of Biochemistry, University College Cork

2005-2007 爱尔兰科克大学，生物化学系，生物技术，硕士

2007-2011 PhD, Pharmacy, School of Pharmacy,University College Cork

2007-2011 爱尔兰科克大学，bat365官网登录入口，药学，博士

工作经历

2018- Professor & Doctoral Supervisor, School of Pharmaceutical Sciences, Jilin University

2018- 吉林大学，bat365官网登录入口，教授，博士生导师

2018-2020 Visiting Scholar, Eshelman School of Pharmacy, UNC at Chapel Hill

2018-2020，北卡罗莱纳大学教堂山分校，bat365官网登录入口，访问学者

2016-2017 Professor & Masters Supervisor,School of Pharmaceutical Sciences, Jilin University

2016-2017 吉林大学，bat365官网登录入口，教授，硕士生导师

2013-2016 Government of Ireland Research Fellow, School of Pharmacy, University College Cork

2013-2016 爱尔兰科克大学，bat365官网登录入口，爱尔兰政府特聘研究员

2012-2013 Study Director, Department of Pharmacology,Viva Biotech

2012-2013 维亚生物科技有限公司，药理部，项目总监

2011-2012 Postdoctoral Researcher, School of Medicine, University of Michigan

2011-2012 美国密西根大学，医学院，博士后

主讲课程

Bioharmaceutics (B)

生物药物制剂学 B

研究领域

Nanoformulation, cancer immunotherapy, tissue regeneration

纳米药物剂型，癌症免疫治疗，组织再生修复

科研成果

Publication：

1.Guo J, Yu Z, Das M, Huang L*. Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis. ACS Nano 2020, 14: 5075-5089.

2.Yang Y, Guo J*, L Huang*, Tackling TAMs for cancer immunotherapy: It's nano time. Trends in Pharmacological Sciences 2020, 41: 701-714.

3.Guo J, Huang L*. Membrane-core nanoparticles for cancer nanomedicine. Advanced Drug Delivery Reviews 2020 doi: 10.1016/j.addr.2020.05.005.

4.Liu Y, Guo J*, Huang L*. Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies. Theranostics 2020, 10: 3099-3117.

5.Luan X, Rahme K, Cong Z, Wang L, Zou Y, He Y, Yang H, Holmes JD, O'Driscoll CM, Guo J*. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice. European Journal of Pharmaceutics and Biopharmaceutics. 2019, 137: 56-67.